• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Hinge Health Reports Second Quarter 2025 Financial Results

    8/5/25 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology
    Get the next $HNGE alert in real time by email

    Hinge Health, Inc. (NYSE:HNGE) today announced financial results for the second quarter ended June 30, 2025.

    "In Q2 we delivered year-over-year revenue growth of 55% and a strong free cash flow margin, underlining the market's embrace of our AI-powered platform," said Daniel Perez, Co-Founder and CEO, Hinge Health. "The journey of automating healthcare delivery will be challenging, but we're excited about our momentum and are moving with haste to capture this opportunity."

    Second Quarter 2025 Financial Highlights:

    • Revenue increased 55% year-over-year to $139.1 million compared to revenue of $89.8 million in Q2 2024.
    • GAAP gross margin was 70% compared to 74% in Q2 2024. Non-GAAP gross margin was 83% compared to 77% in Q2 2024.
    • GAAP loss from operations was $580.7 million, which included $591.0 million in stock-based compensation expense, compared to GAAP loss from operations of $17.6 million in Q2 2024. Non-GAAP income from operations was $26.1 million compared to non-GAAP loss from operations of $14.4 million in Q2 2024.
    • Net cash provided by operating activities was $20.2 million compared to a net cash provided by operating activities of $14.9 million during Q2 2024. Free cash flow was $32.6 million, which included an adjustment of $14.2 million for employer taxes related to stock-based compensation at IPO, compared to free cash flow of $14.0 million during Q2 2024.
    • Cash, cash equivalents, marketable securities and restricted cash were $415.1 million as of June 30, 2025.

    Key Metrics as of June 30, 2025:

    • LTM calculated billings of $568.4 million compared to $367.8 million for Q2 2024, an increase of 55%.
    • Number of clients increased 32% to 2,359 clients compared to 1,785 clients in Q2 2024.

    Financial Outlook:

    We are providing the following guidance for our third quarter and full year 2025:

    • Q3 2025: We expect our revenue to be between $141 million and $143 million, reflecting year-over-year growth of 41% at the midpoint. We expect our non-GAAP income from operations to be between $17 million and $21 million, compared to non-GAAP loss from operations of $3.7 million in Q3 2024.
    • Fiscal Year 2025: We expect our revenue to be between $548 million and $552 million, reflecting year- over-year growth of 41% at the midpoint. We expect our non-GAAP income from operations to be between $77 million and $83 million, compared to non-GAAP loss from operations of $26.1 million in 2024.

    Statement Regarding Use of Non-GAAP Financial Measures

    This press release uses non-GAAP financial measures, which are not calculated in accordance with generally accepted accounting principles of the United States (GAAP). For more information about these non-GAAP financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP, please see the "Non-GAAP Financial Measures" section below.

    Moreover, we have not reconciled our non-GAAP income (loss) from operations guidance to GAAP income (loss) from operations because we do not and are not able to provide guidance for GAAP income (loss) from operations due to the uncertainty and potential variability of stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets and adjustments, such as the excess inventory and transition charges, restructuring and other expense and acquisition related expense, which are reconciling items between non-GAAP and GAAP income (loss) from operations. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measures. However, such items could have a significant impact on our future GAAP income (loss) from operations.

    Hinge Health Earnings Webcast

    We will host a conference call and webcast for investors on August 5, 2025 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss our financial results, business highlights and financial outlook. The live webcast of the conference call can be accessed by registering online at ir.hingehealth.com/events-presentations.

    Following completion of the events, a webcast replay will also be available at ir.hingehealth.com for 12 months.

    About Hinge Health

    Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, a wearable device, and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The Company is headquartered in San Francisco, California.

    Available Information

    Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our Company through a variety of means, including filings with the U.S. Securities and Exchange Commission ("SEC"), the investor relations page on our website (ir.hingehealth.com), press releases, public conference calls, and webcasts in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our obligations under Regulation FD.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," or "will," or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our outlook and guidance for the third quarter of 2025 and guidance for full year 2025 and our assumptions underlying such guidance; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including those more fully described under the caption "Risk Factors" in our Prospectus dated May 21, 2025, filed with the SEC on May 22, 2025, and elsewhere in documents that we file with the SEC, including our Quarterly Report on Form 10-Q for the second quarter ended June 30, 2025, which will be filed with the SEC on or around August 11, 2025. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

    HINGE HEALTH, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    unaudited

    (in thousands, except par value data)

     

     

     

     

     

     

     

     

    June 30,

     

     

    December 31,

     

     

     

    2025

     

     

    2024

     

    Assets

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    237,170

     

     

    $

    300,785

     

    Marketable securities

     

     

    176,087

     

     

     

    165,787

     

    Accounts receivable, net of allowance for credit losses of $7,649 and $6,470

    as of June 30, 2025 and December 31, 2024, respectively

     

     

    99,299

     

     

     

    42,495

     

    Deferred commissions

     

     

    24,354

     

     

     

    18,615

     

    Inventory

     

     

    13,987

     

     

     

    10,873

     

    Prepaid expenses and other current assets

     

     

    47,528

     

     

     

    44,891

     

    Total current assets

     

     

    598,425

     

     

     

    583,446

     

    Goodwill

     

     

    64,096

     

     

     

    61,607

     

    Intangible assets, net

     

     

    2,961

     

     

     

    1,807

     

    Property, equipment and software, net

     

     

    7,724

     

     

     

    7,380

     

    Operating lease right-of-use assets

     

     

    8,605

     

     

     

    9,607

     

    Other assets

     

     

    11,843

     

     

     

    9,412

     

    Total assets

     

    $

    693,654

     

     

    $

    673,259

     

    Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

    Accounts payable and accrued liabilities

     

    $

    34,898

     

     

    $

    27,853

     

    Operating lease liabilities

     

     

    4,047

     

     

     

    3,814

     

    Deferred revenue

     

     

    275,138

     

     

     

    217,632

     

    Total current liabilities

     

     

    314,083

     

     

     

    249,299

     

    Operating lease liabilities, noncurrent

     

     

    5,919

     

     

     

    7,258

     

    Total liabilities

     

     

    320,002

     

     

     

    256,557

     

     

     

     

     

     

     

     

    Redeemable convertible preferred stock:

     

     

     

     

     

     

    Redeemable convertible preferred stock; $0.00001 par value

     

     

    199,874

     

     

     

    851,272

     

    Stockholders' equity (deficit):

     

     

     

     

     

     

    Common stock, $0.00001 par value

     

     

    —

     

     

     

    —

     

    Class A common stock, $0.00001 par value

     

     

    —

     

     

     

    —

     

    Class B common stock, $0.00001 par value

     

     

    —

     

     

     

    —

     

    Additional paid-in capital

     

     

    1,255,059

     

     

     

    88,097

     

    Accumulated other comprehensive gain (loss)

     

     

    (34

    )

     

     

    68

     

    Accumulated deficit

     

     

    (1,081,247

    )

     

     

    (522,735

    )

    Total stockholders' equity (deficit)

     

     

    173,778

     

     

     

    (434,570

    )

    Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)

     

    $

    693,654

     

     

    $

    673,259

     

    HINGE HEALTH, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    unaudited

    (in thousands, except per share data)

     

     

    Three Months Ended June 30,

     

     

    Six Months Ended June 30,

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

    Revenue

     

    $

    139,098

     

     

    $

    89,825

     

     

    $

    262,923

     

     

    $

    172,533

     

    Cost of revenue

     

     

    41,335

     

     

     

    23,208

     

     

     

    64,927

     

     

     

    47,976

     

    Gross profit

     

     

    97,763

     

     

     

    66,617

     

     

     

    197,996

     

     

     

    124,557

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

     

    279,962

     

     

     

    24,920

     

     

     

    303,462

     

     

     

    54,683

     

    Sales and marketing

     

     

    147,228

     

     

     

    44,894

     

     

     

    193,944

     

     

     

    87,037

     

    General and administrative

     

     

    251,244

     

     

     

    14,354

     

     

     

    268,125

     

     

     

    31,812

     

    Total operating expenses

     

     

    678,434

     

     

     

    84,168

     

     

     

    765,531

     

     

     

    173,532

     

    Loss from operations

     

     

    (580,671

    )

     

     

    (17,551

    )

     

     

    (567,535

    )

     

     

    (48,975

    )

    Other income:

     

     

     

     

     

     

     

     

     

     

     

     

    Other income, net

     

     

    4,694

     

     

     

    4,986

     

     

     

    9,695

     

     

     

    10,104

     

    Net loss before income taxes

     

     

    (575,977

    )

     

     

    (12,565

    )

     

     

    (557,840

    )

     

     

    (38,871

    )

    Provision (benefit) for income taxes

     

     

    (326

    )

     

     

    361

     

     

     

    672

     

     

     

    519

     

    Net loss

     

    $

    (575,651

    )

     

    $

    (12,926

    )

     

    $

    (558,512

    )

     

    $

    (39,390

    )

    Adjustment to reflect deemed contribution

    from Series D and Series E redeemable

    convertible preferred stock extinguishment

     

     

    —

     

     

     

    —

     

     

     

    104,174

     

     

     

    —

     

    Net loss attributable to common stockholders

     

    $

    (575,651

    )

     

    $

    (12,926

    )

     

    $

    (454,338

    )

     

    $

    (39,390

    )

    Net loss per share attributable to common

    stockholders, basic and diluted

     

    $

    (13.10

    )

     

    $

    (0.96

    )

     

    $

    (15.05

    )

     

    $

    (2.93

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted average shares attributable to

    common stockholders, basic and diluted

     

     

    43,931

     

     

     

    13,528

     

     

     

    30,190

     

     

     

    13,455

     

    HINGE HEALTH, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    unaudited

    (in thousands)

     

     

     

     

     

     

     

     

    Three Months Ended June 30,

     

     

    Six Months Ended June 30,

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

    Operating activities

     

     

     

     

     

     

     

     

     

     

     

     

    Net loss

     

    $

    (575,651

    )

     

    $

    (12,926

    )

     

    $

    (558,512

    )

     

    $

    (39,390

    )

    Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

     

     

     

     

     

     

     

     

     

     

     

     

    Depreciation and amortization

     

     

    1,343

     

     

     

    1,554

     

     

     

    2,646

     

     

     

    3,168

     

    Stock-based compensation

     

     

    590,983

     

     

     

    306

     

     

     

    590,990

     

     

     

    610

     

    Amortization of deferred commissions

     

     

    10,680

     

     

     

    7,147

     

     

     

    19,870

     

     

     

    13,411

     

    Accretion of discounts and amortization of premiums on

    marketable securities, net

     

     

    277

     

     

     

    11

     

     

     

    326

     

     

     

    217

     

    Excess and obsolete inventory charge

     

     

    —

     

     

     

    1,309

     

     

     

    —

     

     

     

    1,812

     

    Non-cash operating lease expense

     

     

    843

     

     

     

    925

     

     

     

    1,688

     

     

     

    1,833

     

    Provision for credit losses

     

     

    1,894

     

     

     

    1,570

     

     

     

    2,780

     

     

     

    2,487

     

    Deferred income taxes

     

     

    90

     

     

     

    —

     

     

     

    96

     

     

     

    —

     

    Other

     

     

    2

     

     

     

    (6

    )

     

     

    (2

    )

     

     

    (3

    )

    Changes in operating assets and liabilities:

     

     

     

     

     

     

     

     

     

     

     

     

    Accounts receivable

     

     

    (25,304

    )

     

     

    (6,069

    )

     

     

    (59,584

    )

     

     

    (23,281

    )

    Deferred commissions

     

     

    (17,020

    )

     

     

    (11,165

    )

     

     

    (27,650

    )

     

     

    (18,171

    )

    Inventory

     

     

    (1,202

    )

     

     

    (402

    )

     

     

    (3,114

    )

     

     

    1,137

     

    Prepaid expenses and other current assets

     

     

    (14,743

    )

     

     

    4,163

     

     

     

    (6,609

    )

     

     

    1,295

     

    Other assets

     

     

    (211

    )

     

     

    (283

    )

     

     

    (485

    )

     

     

    239

     

    Accounts payable and accrued liabilities

     

     

    (8,713

    )

     

     

    (15,574

    )

     

     

    6,997

     

     

     

    (7,661

    )

    Operating lease liabilities

     

     

    (851

    )

     

     

    (1,195

    )

     

     

    (1,792

    )

     

     

    (2,372

    )

    Deferred revenue

     

     

    57,810

     

     

     

    45,558

     

     

     

    57,505

     

     

     

    46,934

     

    Net cash provided by (used in) operating activities

     

     

    20,227

     

     

     

    14,923

     

     

     

    25,150

     

     

     

    (17,735

    )

    Investing activities:

     

     

     

     

     

     

     

     

     

     

     

     

    Purchase of property and equipment

     

     

    (197

    )

     

     

    (437

    )

     

     

    (248

    )

     

     

    (567

    )

    Capitalized internal use software

     

     

    (1,630

    )

     

     

    (497

    )

     

     

    (2,336

    )

     

     

    (1,316

    )

    Purchases of marketable securities

     

     

    (85,110

    )

     

     

    (84,453

    )

     

     

    (175,282

    )

     

     

    (160,768

    )

    Maturities of marketable securities

     

     

    90,958

     

     

     

    88,056

     

     

     

    164,556

     

     

     

    181,550

     

    Acquisition of a business

     

     

    —

     

     

     

    —

     

     

     

    (4,000

    )

     

     

    —

     

    Net cash provided by (used in) investing activities

     

     

    4,021

     

     

     

    2,669

     

     

     

    (17,310

    )

     

     

    18,899

     

    Financing activities:

     

     

     

     

     

     

     

     

     

     

     

     

    Proceeds from exercise of stock options

     

     

    159

     

     

     

    218

     

     

     

    256

     

     

     

    277

     

    Proceeds from issuance of common stock in initial public

    offering, net of issuance costs

     

     

    255,675

     

     

     

    —

     

     

     

    255,675

     

     

     

    —

     

    Tax withholdings on settlement of restricted

    stock units and performance-based restricted stock units

     

     

    (272,258

    )

     

     

    —

     

     

     

    (272,258

    )

     

     

    —

     

    Payment on Repurchase Agreement with Coatue

     

     

    (50,000

    )

     

     

    —

     

     

     

    (50,000

    )

     

     

    —

     

    Proceeds from repayment of non-recourse loans

    to employees

     

     

    —

     

     

     

    —

     

     

     

    4,934

     

     

     

    —

     

    Payments for deferred offering costs

     

     

    (9,134

    )

     

     

    (125

    )

     

     

    (10,061

    )

     

     

    (125

    )

    Net cash provided by (used in)

    financing activities

     

     

    (75,558

    )

     

     

    93

     

     

     

    (71,454

    )

     

     

    152

     

    Net increase (decrease) in cash

     

     

    (51,310

    )

     

     

    17,685

     

     

     

    (63,614

    )

     

     

    1,316

     

    Cash, cash equivalents and restricted cash, beginning of period

     

     

    290,282

     

     

     

    221,105

     

     

     

    302,586

     

     

     

    237,474

     

    Cash, cash equivalents and restricted cash, end of period

     

    $

    238,972

     

     

    $

    238,790

     

     

    $

    238,972

     

     

    $

    238,790

     

    Reconciliation of cash, cash equivalents and restricted cash

    to the consolidated balance sheets:

     

     

     

     

     

     

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    237,170

     

     

    $

    236,628

     

     

    $

    237,170

     

     

    $

    236,628

     

    Restricted cash

     

     

    1,802

     

     

     

    2,162

     

     

     

    1,802

     

     

     

    2,162

     

    Total cash, cash equivalents and restricted cash

     

    $

    238,972

     

     

    $

    238,790

     

     

    $

    238,972

     

     

    $

    238,790

     

    Glossary of Terms

    LTM Calculated Billings: We believe calculated billings on a last 12-months basis helps investors better understand our performance for a particular period given the seasonality in our model due to quarterly fluctuations based on the timing of new client launches and number of intra-year launches. We anticipate that this seasonality will continue and therefore focus on LTM calculated billings. Our revenue generally does not reflect this seasonality and these quarterly fluctuations given that we recognize revenue ratably over the term that members have access to our platform. LTM calculated billings are defined as total revenue, plus the change in deferred revenue, less the change in contract assets for a given 12-month period.

    Number of Clients: We view this number as an important metric to assess the performance of our business as an increased number of clients drives growth, increases brand awareness, and helps provide scale to our business. Clients are defined as businesses or organizations, which we call entities, that have at least one active agreement with us at the end of a particular period. Entities that procure our platform through our partners are counted as individual clients. We do not count our partners as clients, unless they also separately have at least one active client agreement with us. When a partner has an agreement with us for their fully-insured population, that partner is deemed to be one client, despite there being multiple fully-insured employers within that entity that have access to our platform.

    Non-GAAP Financial Measures

    In addition to our results prepared in accordance with GAAP, we believe the following non-GAAP financial measures, including non-GAAP gross profit and gross margin, non-GAAP income (loss) from operations and operating margin, non-GAAP operating expenses, and free cash flow and free cash flow margin included in this press release, provide users of our financial information with additional useful information in evaluating our performance and liquidity and allows them to more readily compare our results across periods without the effect of non-cash and other items as detailed below. Additionally, our management and board of directors use our non-GAAP financial measures to evaluate our performance and liquidity, identify trends and make strategic decisions.

    There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes. Our non-GAAP financial measures should not be considered in isolation or as alternatives to gross profit, gross margin, income (loss) from operations, net cash provided by (used in) operating activities or any other measure of financial performance calculated and presented in accordance with GAAP.

    Non-GAAP Gross Profit and Gross Margin

    We define non-GAAP gross profit as gross profit presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including excess and obsolete inventory charges related to our AI-powered motion tracking technology transition, stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets, and restructuring and other expenses. We define non-GAAP gross margin as non-GAAP gross profit divided by revenue.

    The principal limitation of non-GAAP gross profit and non-GAAP gross margin is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

    Non-GAAP Income (Loss) From Operations and Operating Margin

    We define non-GAAP income (loss) from operations as income (loss) from operations presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including excess and obsolete inventory charges related to our AI-powered motion tracking technology transition, stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets, restructuring and other expenses and acquisition-related expenses. We define non-GAAP operating margin as non-GAAP income (loss) from operations divided by revenue.

    The principal limitation of non-GAAP income (loss) from operations and non-GAAP operating margin is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

    Non-GAAP Operating Expenses

    We define non-GAAP operating expenses as operating expenses presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including stock-based compensation expense, employer payroll tax expense related to stock-based compensation, restructuring and other expenses and acquisition-related expenses.

    The principal limitation of non-GAAP research and development expenses, non-GAAP sales and marketing expenses and non-GAAP general and administrative expenses is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

    Free Cash Flow and Free Cash Flow Margin

    We define free cash flow as net cash provided by (used in) operating activities plus cash used for employer payroll taxes related to pre-IPO stock-based compensation less purchases of property, equipment and software (including capitalized internal-use software). We believe that free cash flow is a helpful indicator of liquidity that provides information to management and investors about the amount of cash generated or used by our operations that, after taking into account the employer payroll taxes paid as part of the vesting of shares at IPO as well as investments in property, equipment and software (including capitalized internal-use software), can be used for strategic initiatives, including investing in our business and strengthening our financial position. The principal limitation of free cash flow is that it does not represent the total increase or decrease in our cash balance for a given period. We define free cash flow margin as free cash flow divided by revenue.

    We adjust the following items from one or more of our non-GAAP financial measures:

    Excess and obsolete inventory charges. We exclude certain charges related to excess and obsolete inventory related to our AI-powered motion tracking technology transition, which was our strategic decision in the first half of 2023 to shift away from providing kits with tablets and wearable sensors. As part of this shift, we began to provide access to our platform through our app on members' personal smartphones or tablets and replaced sensors for members with our proprietary AI-powered motion tracking technology. We exclude these charges because we do not believe these expenses have a direct correlation to the operating performance of our business.

    Stock-based compensation expense. We exclude stock-based compensation expense, which is a non-cash expense, from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding our operating performance.

    Employer payroll tax expense related to stock-based compensation. We exclude expenses for employer payroll taxes related to stock-based compensation from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding operational performance. In particular, this expense is tied to the exercise, vesting or sale of underlying equity awards and the price of our common stock at the time of exercise, vesting or sale which may vary from period to period independent of the operating performance of our business.

    Amortization of intangible assets. We exclude amortization of intangible assets, which is a non-cash expense, from certain of our non-GAAP financial measures. Our expenses for amortization of intangible assets are inconsistent in amount and frequency because they are significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. We exclude these amortization expenses because we do not believe these expenses have a direct correlation to the operating performance of our business.

    Restructuring and other expenses. We exclude certain charges that are mainly attributable to workforce reduction in order to simplify our operations and better align our resources with our priorities. We exclude these charges because we do not believe these charges have a direct correlation to the operating performance of our business.

    Acquisition-related expenses. We exclude certain charges that are attributable to acquiring businesses. We exclude these charges because we do not believe these charges have a direct correlation to the operating performance of our business.

    HINGE HEALTH, INC.

    unaudited

    (in thousands, except percentages)

    Reconciliation of GAAP to Non-GAAP Financial Measures:

     

     

    Three Months Ended

    June 30,

     

     

    Six Months Ended

    June 30,

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

    GAAP gross profit

     

    $

    97,763

     

     

    $

    66,617

     

     

    $

    197,996

     

     

    $

    124,557

     

    GAAP gross margin

     

     

    70

    %

     

     

    74

    %

     

     

    75

    %

     

     

    72

    %

    Excess and obsolete inventory charges (1)

     

     

    —

     

     

     

    1,309

     

     

     

    —

     

     

     

    1,812

     

    Stock-based compensation expense (2)

     

     

    16,441

     

     

     

    37

     

     

     

    16,441

     

     

     

    72

     

    Employer payroll tax expense related to stock-based compensation

     

     

    893

     

     

     

    —

     

     

     

    893

     

     

     

    —

     

    Amortization of intangible assets

     

     

    225

     

     

     

    95

     

     

     

    406

     

     

     

    189

     

    Restructuring and other expenses

     

     

    —

     

     

     

    711

     

     

     

    —

     

     

     

    711

     

    Non-GAAP gross profit

     

    $

    115,322

     

     

    $

    68,769

     

     

    $

    215,736

     

     

    $

    127,341

     

    Non-GAAP gross margin

     

     

    83

    %

     

     

    77

    %

     

     

    82

    %

     

     

    74

    %

     

     

    Three Months Ended

    June 30,

     

     

    Six Months Ended

    June 30,

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

    GAAP loss from operations

     

    $

    (580,671

    )

     

    $

    (17,551

    )

     

    $

    (567,535

    )

     

    $

    (48,975

    )

    GAAP operating margin

     

     

    (417

    )%

     

     

    (20

    )%

     

     

    (216

    )%

     

     

    (28

    )%

    Excess and obsolete inventory charges (1)

     

     

    —

     

     

     

    1,309

     

     

     

    —

     

     

     

    1,812

     

    Stock-based compensation expense (2)

     

     

    590,983

     

     

     

    306

     

     

     

    590,990

     

     

     

    610

     

    Employer payroll tax expense related to stock-based compensation

     

     

    14,227

     

     

     

    (6,253

    )

     

     

    14,227

     

     

     

    (6,253

    )

    Amortization of intangible assets

     

     

    225

     

     

     

    95

     

     

     

    406

     

     

     

    189

     

    Restructuring and other expenses

     

     

    —

     

     

     

    7,599

     

     

     

    —

     

     

     

    8,671

     

    Acquisition-related expenses

     

     

    1,337

     

     

     

    100

     

     

     

    2,968

     

     

     

    100

     

    Non-GAAP income (loss) from operations

     

    $

    26,101

     

     

    $

    (14,395

    )

     

    $

    41,056

     

     

    $

    (43,846

    )

    Non-GAAP operating margin

     

     

    19

    %

     

     

    (16

    )%

     

     

    16

    %

     

     

    (25

    )%

    (1)

     

    Reflects our strategic decision in the first half of 2023 to shift away from providing kits with tablets and wearable sensors. As part of this shift, we began to provide access to our platform through our app on members' personal smartphones or tablets and replaced all sensors for members with our proprietary AI-powered motion tracking technology.

     

     

     

    (2)

     

    Stock-based compensation expense:

     

     

    Three Months Ended

    June 30,

     

     

    Six Months Ended

    June 30,

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

    Cost of revenue

     

    $

    16,441

     

     

    $

    37

     

     

    $

    16,441

     

     

    $

    72

     

    Research and development

     

     

    248,809

     

     

     

    81

     

     

     

    248,809

     

     

     

    161

     

    Sales and marketing

     

     

    95,050

     

     

     

    89

     

     

     

    95,050

     

     

     

    181

     

    General and administrative

     

     

    230,683

     

     

     

    99

     

     

     

    230,690

     

     

     

    196

     

     

     

    $

    590,983

     

     

    $

    306

     

     

    $

    590,990

     

     

    $

    610

     

    HINGE HEALTH, INC.

    unaudited

    (in thousands, except for percentages)

     

     

    Three Months Ended

    June 30,

     

     

    Six Months Ended

    June 30,

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

    GAAP research and development

     

    $

    279,962

     

     

    $

    24,920

     

     

    $

    303,462

     

     

    $

    54,683

     

    GAAP research and development as a percentage of revenue

     

     

    201

    %

     

     

    28

    %

     

     

    115

    %

     

     

    32

    %

    Stock-based compensation expense (2)

     

     

    (248,809

    )

     

     

    (81

    )

     

     

    (248,809

    )

     

     

    (161

    )

    Employer payroll tax expense related to stock-based compensation

     

     

    (7,020

    )

     

     

    2,852

     

     

     

    (7,020

    )

     

     

    2,852

     

    Restructuring and other expenses

     

     

    —

     

     

     

    (3,428

    )

     

     

    —

     

     

     

    (4,394

    )

    Acquisition-related expenses

     

     

    (1,358

    )

     

     

    —

     

     

     

    (2,816

    )

     

     

    —

     

    Non-GAAP research and development

     

    $

    22,775

     

     

    $

    24,263

     

     

    $

    44,817

     

     

    $

    52,980

     

    Non-GAAP research and development as a percentage of revenue

     

     

    16

    %

     

     

    27

    %

     

     

    17

    %

     

     

    31

    %

     

     

    Three Months Ended

    June 30,

     

     

    Six Months Ended

    June 30,

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

    GAAP sales and marketing

     

    $

    147,228

     

     

    $

    44,894

     

     

    $

    193,944

     

     

    $

    87,037

     

    GAAP sales and marketing as a percentage of revenue

     

     

    106

    %

     

     

    50

    %

     

     

    74

    %

     

     

    50

    %

    Stock-based compensation expense (2)

     

     

    (95,050

    )

     

     

    (89

    )

     

     

    (95,050

    )

     

     

    (181

    )

    Employer payroll tax expense related to stock-based compensation

     

     

    (2,630

    )

     

     

    —

     

     

     

    (2,630

    )

     

     

    —

     

    Restructuring and other expenses

     

     

    —

     

     

     

    (2,004

    )

     

     

    —

     

     

     

    (2,053

    )

    Non-GAAP sales and marketing

     

    $

    49,548

     

     

    $

    42,801

     

     

    $

    96,264

     

     

    $

    84,803

     

    Non-GAAP sales and marketing as a percentage of revenue

     

     

    36

    %

     

     

    48

    %

     

     

    37

    %

     

     

    49

    %

     

     

    Three Months Ended

    June 30,

     

     

    Six Months Ended

    June 30,

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

    GAAP general and administrative

     

    $

    251,244

     

     

    $

    14,354

     

     

    $

    268,125

     

     

    $

    31,812

     

    GAAP general and administrative as a percentage of revenue

     

     

    181

    %

     

     

    16

    %

     

     

    102

    %

     

     

    18

    %

    Stock-based compensation expense (2)

     

     

    (230,683

    )

     

     

    (99

    )

     

     

    (230,690

    )

     

     

    (196

    )

    Employer payroll tax expense related to stock-based compensation

     

     

    (3,684

    )

     

     

    3,401

     

     

     

    (3,684

    )

     

     

    3,401

     

    Restructuring and other expenses

     

     

    —

     

     

     

    (1,456

    )

     

     

    —

     

     

     

    (1,512

    )

    Acquisition-related expenses

     

     

    22

     

     

     

    (100

    )

     

     

    (153

    )

     

     

    (100

    )

    Non-GAAP general and administrative

     

    $

    16,899

     

     

    $

    16,100

     

     

    $

    33,598

     

     

    $

    33,405

     

    Non-GAAP general and administrative as a percentage of revenue

     

     

    12

    %

     

     

    18

    %

     

     

    13

    %

     

     

    19

    %

    (2)

     

    For details on stock-based compensation expense, see above.

     

     

    Three Months Ended June 30,

     

     

    Six Months Ended June 30,

     

     

     

    2025

     

     

    2024

     

     

    2025

     

     

    2024

     

    Net cash provided by (used in) operating activities

     

    $

    20,227

     

     

    $

    14,923

     

     

    $

    25,150

     

     

    $

    (17,735

    )

    Operating cash flow margin

     

     

    15

    %

     

     

    17

    %

     

     

    10

    %

     

     

    (10

    )%

    Adjustment for employer taxes related to pre-IPO stock-based compensation

     

     

    14,227

     

     

     

    —

     

     

     

    14,227

     

     

     

    —

     

    Less purchases of property, equipment and software

    (including capitalized internal use software)

     

     

    (1,827

    )

     

     

    (934

    )

     

     

    (2,584

    )

     

     

    (1,883

    )

    Free cash flow

     

    $

    32,627

     

     

    $

    13,989

     

     

    $

    36,793

     

     

    $

    (19,618

    )

    Free cash flow margin

     

     

    23

    %

     

     

    16

    %

     

     

    14

    %

     

     

    (11

    )%

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250804388687/en/

    Investor Relations Contact:

    [email protected]

    Media Contact:

    [email protected]

    Get the next $HNGE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HNGE

    DatePrice TargetRatingAnalyst
    7/14/2025$58.00Mkt Outperform
    Citizens JMP
    6/16/2025Outperform
    William Blair
    6/16/2025$48.00Buy
    Truist
    6/16/2025$48.00Buy
    Stifel
    6/16/2025$45.00Outperform
    Raymond James
    6/16/2025$41.00Overweight
    Piper Sandler
    6/16/2025$46.00Overweight
    Morgan Stanley
    6/16/2025$47.00Buy
    Needham
    More analyst ratings

    $HNGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hinge Health Reports Second Quarter 2025 Financial Results

    Hinge Health, Inc. (NYSE:HNGE) today announced financial results for the second quarter ended June 30, 2025. "In Q2 we delivered year-over-year revenue growth of 55% and a strong free cash flow margin, underlining the market's embrace of our AI-powered platform," said Daniel Perez, Co-Founder and CEO, Hinge Health. "The journey of automating healthcare delivery will be challenging, but we're excited about our momentum and are moving with haste to capture this opportunity." Second Quarter 2025 Financial Highlights: Revenue increased 55% year-over-year to $139.1 million compared to revenue of $89.8 million in Q2 2024. GAAP gross margin was 70% compared to 74% in Q2 2024. Non-GAAP gr

    8/5/25 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health to announce second quarter 2025 financial results on August 5, 2025

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the quarterly period ended June 30, 2025, after the close of the market on Tuesday, August 5, 2025. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting w

    7/8/25 4:30:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health Announces HingeSelect - a High-performance Network Delivering Unified Musculoskeletal Care

    Combined with Hinge Health's AI-powered exercise therapy program, HingeSelect adds access to high-quality in-person providers for members at up to 50% below PPO rates Hinge Health, Inc. (NYSE:HNGE), today announced the launch of HingeSelect, a high-performance provider network for musculoskeletal (MSK) care. Hinge Health's technology and in-house orthopedic physicians triage and direct downstream care, prioritizing the most appropriate evidence-based treatment. When in-person care, such as imaging or injections is required, members are seamlessly connected to pre-vetted providers at up to 50% below PPO rates. Combined with Hinge Health's AI-powered digital exercise therapy, HingeSelect pr

    6/17/25 9:00:00 AM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens JMP initiated coverage on Hinge Health with a new price target

    Citizens JMP initiated coverage of Hinge Health with a rating of Mkt Outperform and set a new price target of $58.00

    7/14/25 8:51:47 AM ET
    $HNGE
    EDP Services
    Technology

    William Blair initiated coverage on Hinge Health

    William Blair initiated coverage of Hinge Health with a rating of Outperform

    6/16/25 7:49:34 AM ET
    $HNGE
    EDP Services
    Technology

    Truist initiated coverage on Hinge Health with a new price target

    Truist initiated coverage of Hinge Health with a rating of Buy and set a new price target of $48.00

    6/16/25 7:49:23 AM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Hinge Health Inc.

    SCHEDULE 13G - Hinge Health, Inc. (0001673743) (Subject)

    8/14/25 5:37:04 PM ET
    $HNGE
    EDP Services
    Technology

    SEC Form SCHEDULE 13G filed by Hinge Health Inc.

    SCHEDULE 13G - Hinge Health, Inc. (0001673743) (Subject)

    8/14/25 4:56:48 PM ET
    $HNGE
    EDP Services
    Technology

    SEC Form SCHEDULE 13G filed by Hinge Health Inc.

    SCHEDULE 13G - Hinge Health, Inc. (0001673743) (Subject)

    8/14/25 4:35:39 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Co-Founder Perez Daniel Antonio exercised 35,470 shares at a strike of $1.08 (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    8/6/25 4:13:45 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Financials

    Live finance-specific insights

    View All

    Hinge Health Reports Second Quarter 2025 Financial Results

    Hinge Health, Inc. (NYSE:HNGE) today announced financial results for the second quarter ended June 30, 2025. "In Q2 we delivered year-over-year revenue growth of 55% and a strong free cash flow margin, underlining the market's embrace of our AI-powered platform," said Daniel Perez, Co-Founder and CEO, Hinge Health. "The journey of automating healthcare delivery will be challenging, but we're excited about our momentum and are moving with haste to capture this opportunity." Second Quarter 2025 Financial Highlights: Revenue increased 55% year-over-year to $139.1 million compared to revenue of $89.8 million in Q2 2024. GAAP gross margin was 70% compared to 74% in Q2 2024. Non-GAAP gr

    8/5/25 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health to announce second quarter 2025 financial results on August 5, 2025

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the quarterly period ended June 30, 2025, after the close of the market on Tuesday, August 5, 2025. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting w

    7/8/25 4:30:00 PM ET
    $HNGE
    EDP Services
    Technology